Sarepta's Duchenne gene therapy misses main goal in study
Sarepta Therapeutics(US:SRPT) Reuters·2025-11-04 05:24Sarepta said on Monday that its late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not meet the main goal. ...